N/A N=10 N-of-few Study of Pain Perception
Healthy
Primary: Within Participant Subjective Ratings of Acute Thermal Pain Following High Compared to Low Cues (Learned Via Symbolic Learning) — 7.32 score on a scale — p=0.043
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=232 Inpatient Enrollment of Patient Portal App
Orthopedic Disorder
Primary: Return to Clinic — 97; 93 Participants — p=.0574
Phase 2 N=53 A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs Against COVID-19.
COVID-19
Primary: Number of Participants That Were Hospitalized Due to COVID-19 Symptoms — 0; 0; 0; 0 Participants
Phase 2 N=58 An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy
Spinal Muscular Atrophy · Spinal Muscular Atrophy Type 3 · Spinal Muscular Atrophy Type 2
Primary: Cohort 1: Change From Baseline in the Revised Hammersmith Scale (RHS) Total Score at Day 364 (Visit 15) [Month 12] — -0.1; 0.0 score on a scale
N/A N=15 Ultravision™ System to Facilitate Low Impact Laparoscopic Surgery for Endometriosis
Endometriosis
Primary: Procedure Completed Without Change in Intra-abdominal Pressure — 9 Participants
Phase 2 N=138 Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma
Lymphoma
Primary: Toxicity as Assessed by NCI CTCAE v3.0 (Phase I) — 3; 3; 5; 2 Participants
Phase 2 N=232 An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection
Hepatitis B
Primary: Change From Baseline in Hepatitis B Surface Antigen (HBsAg) Levels in Currently Not Treated Population at Week 24 — -0.251; -0.096; -0.142; -0.203 log10 IU per…
Phase 2 N=14 Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway
Castration Levels of Testosterone · Castration-Resistant Prostate Carcinoma · Metastatic Prostate Carcinoma
Primary: Proportion of Patients With PSA Decline by 50% From Baseline — 9; 5 Participants
Phase 4 N=84 Stress & Premenstrual Symptoms Study
PMDD · Stress · Mood
Primary: Acoustic Startle Response (ASR) Magnitude Based on Menstrual Cycle Phase — 54.2; 53.7; 56.4; 53.3 t score — p=0.139
N/A N=145 Post Market Study of Parietene™ DS Composite Mesh in Ventral Hernia Repair
Ventral Hernia
Primary: Number of Participants With Hernia Recurrence Within 12 Months Following Parietene™ DS Composite Mesh Use in Ventral Hernia Repair — 4; 116 Participants
Phase 2 N=19 Sildenafil for the Treatment of Lymphatic Malformations
Lymphatic Malformations · Lymphatic Diseases
Primary: Change in Lesion Volume of the Test Medication as Evaluated by MRI Examination. — 5.89; -8.54; -0.642 percentage of volume
Phase 3 N=1,035 A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease
Crohn Disease
Primary: Induction Phase: Cohort 1: Percentage of Participants With Clinical Remission at Week 14 — 11.9; 20.00; 27.3 Percentage of Particiapnts
N/A N=8 Isolating Mechanisms in the Treatment of Borderline Personality Disorder
Borderline Personality Disorder
Primary: Multidimensional Experiential Avoidance Questionnaire - Distress Aversion Subscale — 23.21; 23.21; 19.93; 19.93 score on a scale
Phase 4 N=128 Safety and Efficacy of Dexmedetomidine (DEX) for Sedation of Subjects ≥1 Month to <17 Years Undergoing MRI Scans
MRI Sedation
Primary: Percentage of Participants at the DEX High Dose Versus Low Dose in the Combined Age Cohorts Who Did Not Require Concomitant PRO to Complete MRI — 63.2; 14.3 Percentage…
N/A N=28 Pattern - Reach Aim 2
Obesity
Primary: Number of Participants Satisfied or Very Satisfied With Information Given to Them, as Measured by Follow up Questionnaire — 4; 2 Participants